JP2024531910A5 - - Google Patents

Info

Publication number
JP2024531910A5
JP2024531910A5 JP2024506481A JP2024506481A JP2024531910A5 JP 2024531910 A5 JP2024531910 A5 JP 2024531910A5 JP 2024506481 A JP2024506481 A JP 2024506481A JP 2024506481 A JP2024506481 A JP 2024506481A JP 2024531910 A5 JP2024531910 A5 JP 2024531910A5
Authority
JP
Japan
Prior art keywords
seq
genetically modified
modified immune
car
intracellular signaling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531910A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/039487 external-priority patent/WO2023014922A1/en
Publication of JP2024531910A publication Critical patent/JP2024531910A/ja
Publication of JP2024531910A5 publication Critical patent/JP2024531910A5/ja
Pending legal-status Critical Current

Links

JP2024506481A 2021-08-04 2022-08-04 Lat活性化キメラ抗原受容体t細胞及びその使用方法 Pending JP2024531910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163229344P 2021-08-04 2021-08-04
US63/229,344 2021-08-04
US202263321549P 2022-03-18 2022-03-18
US63/321,549 2022-03-18
PCT/US2022/039487 WO2023014922A1 (en) 2021-08-04 2022-08-04 Lat activating chimeric antigen receptor t cells and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2024531910A JP2024531910A (ja) 2024-09-03
JP2024531910A5 true JP2024531910A5 (cg-RX-API-DMAC7.html) 2025-08-12

Family

ID=83598590

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506481A Pending JP2024531910A (ja) 2021-08-04 2022-08-04 Lat活性化キメラ抗原受容体t細胞及びその使用方法

Country Status (7)

Country Link
US (1) US20250114452A1 (cg-RX-API-DMAC7.html)
EP (1) EP4380967A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024531910A (cg-RX-API-DMAC7.html)
AU (1) AU2022324040A1 (cg-RX-API-DMAC7.html)
CA (1) CA3228262A1 (cg-RX-API-DMAC7.html)
IL (1) IL310550A (cg-RX-API-DMAC7.html)
WO (1) WO2023014922A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221844A2 (en) * 2021-04-13 2022-10-20 WUGEN, Inc. Improved chimeric antigen receptors and uses thereof
WO2026003364A1 (en) * 2024-06-27 2026-01-02 Vanudis GmbH Chimeric coreceptors

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5420032A (en) 1991-12-23 1995-05-30 Universitge Laval Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US6396804B2 (en) 1996-05-28 2002-05-28 Qualcomm Incorporated High data rate CDMA wireless communication system
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
US5950211A (en) 1997-01-03 1999-09-07 Ncr Corporation Discarded history method for solving streams message block leakages
EP0970128A1 (en) 1997-03-21 2000-01-12 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6036355A (en) 1997-07-14 2000-03-14 Quantum Technologies, Inc. Reactor mixing assembly
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20060206949A1 (en) 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
JP5675109B2 (ja) 2007-02-20 2015-02-25 アナプティスバイオ インコーポレイティッド ライブラリーの生成方法及びその使用
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010129418A1 (en) * 2009-05-07 2010-11-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lat adapter molecule for enhanced t-cell signaling and method of use
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3053932B1 (en) 2010-02-19 2020-07-22 Xencor, Inc. Novel ctla4-ig immunoadhesins
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
SG10201806573TA (en) 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
WO2014015457A1 (zh) 2012-07-23 2014-01-30 Chan Kin Sang Tony 便携式空气调节装置
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
US9550998B2 (en) 2012-08-29 2017-01-24 Nature Technology Corporation DNA plasmids with improved expression
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US20150322439A1 (en) 2012-11-19 2015-11-12 Nature Technology Corporation Replicative minicircle vectors with improved expression
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
EP3172231B1 (en) * 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
TWI833684B (zh) * 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
JP7012645B2 (ja) * 2016-01-11 2022-01-28 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー キメラタンパク質および免疫治療の方法
SG11201807489PA (en) * 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
JP2020532987A (ja) * 2017-09-08 2020-11-19 ポセイダ セラピューティクス,インコーポレイティド キメラリガンド受容体(clr)介在性の条件遺伝子発現のための組成物および方法
AU2019240068B2 (en) 2018-03-21 2025-03-13 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
KR20250116790A (ko) 2018-12-12 2025-08-01 카이트 파마 인코포레이티드 키메라 항원 수용체 및 car-t 세포 및 사용 방법
AU2019397152A1 (en) * 2018-12-14 2021-06-24 2Seventy Bio, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020172627A2 (en) * 2019-02-22 2020-08-27 Refuge Biotechnologies, Inc. Chimeric polypeptides and methods of using the same
AU2020231810B2 (en) * 2019-03-01 2025-12-18 National University Of Singapore Engineered immune cells
JP7711945B2 (ja) 2019-04-30 2025-07-23 センティ バイオサイエンシズ インコーポレイテッド キメラ受容体及びその使用方法
MX2021015495A (es) * 2019-06-14 2022-04-18 2Seventy Bio Inc Composiciones y métodos para tratar cáncer.

Similar Documents

Publication Publication Date Title
JP7741732B2 (ja) Bcmaを標的とする操作された免疫細胞及びその使用
JP2022550899A5 (cg-RX-API-DMAC7.html)
JP2019537433A5 (cg-RX-API-DMAC7.html)
JP2022541441A5 (cg-RX-API-DMAC7.html)
JP2025023921A (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2022002546A (ja) 細胞
JP2022548943A5 (cg-RX-API-DMAC7.html)
Spear et al. Strategies to genetically engineer T cells for cancer immunotherapy
JP7590034B2 (ja) Nkg2aを標的にする抗体及びその使用
JP2021505131A5 (cg-RX-API-DMAC7.html)
CN110461335A (zh) 用于治疗bcma相关癌症和自身免疫性失调的联合疗法
EP4729532A2 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
TW201904997A (zh) 引導及導航控制蛋白質以及彼之製造及使用方法
JP2022510207A5 (cg-RX-API-DMAC7.html)
RU2021121771A (ru) Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
JP2025517138A5 (cg-RX-API-DMAC7.html)
US20200354451A1 (en) Chimeric antigen receptors comprising a human transferrin epitope sequence
JP2023549098A5 (cg-RX-API-DMAC7.html)
JP2023545907A (ja) 新規共刺激ドメインを含むキメラ抗原受容体及びその使用
JP2023548829A5 (cg-RX-API-DMAC7.html)
US20240123068A1 (en) Cd19 binders, car-t constructs comprising the same, and methods of using the same
JP2024525492A5 (cg-RX-API-DMAC7.html)
US20240226154A9 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
JP2019536469A5 (cg-RX-API-DMAC7.html)
JP2023516067A5 (cg-RX-API-DMAC7.html)